Picture Kentro Design Corporate and Web Design for Start Ups 2x 650x80px
Document › Details

Bayer AG. (2/4/22). "Press Release: Bayer Will Discontinue Phase II Development Candidate eliapixant [only for specialized press]". Berlin.

Organisations Organisation Evotec SE (FSE: EVT, MDA X/TecDAX, Nasdaq: EVO)
  Group Evotec (Group)
  Organisation 2 Bayer Pharma division
  Group Bayer (Group)
Products Product eliapixant (BAY 1817080)
  Product 2 phase 2 study

Record changed: 2022-02-07


Picture [iito] Made Without Love 650x100px

More documents for Evotec (Group)

To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to and simply fill the subject line with the word »LSE Newsletter«

Find more infos about advertising at [iito] web portals in our media flyer [iito] in a Nutshell [PDF file]


Picture ConsulTech GmbH Berlin Grant Application and Coordination 650x80px

» top